Miromatrix Medical Closes $50M IPO

Miromatrix Medical, a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives, closed its $50 million initial public offering (IPO) of 5,520,000 shares of its common stock at a public offering price of $9 per share, which began trading on the Nasdaq Stock Market on June 24, 2021 under the ticker symbol MIRO. Faegre Drinker represented Miromatrix Medical in the IPO, with professionals from the corporate, executive compensation, corporate governance, FDA and health care regulatory, tax, Delaware corporate and capital markets practices resident in the Minneapolis, Philadelphia, Washington, D.C., Indianapolis, Boulder, New York and Wilmington offices advising on the transaction.